Go to
JCI Insight
Stefanie Dimmeler, … , Andreas M. Zeiher, Michael D. Schneider
Published March 1, 2005
Citation Information: J Clin Invest. 2005;115(3):572-583. https://doi.org/10.1172/JCI24283.
Citation Information: J Clin Invest. 2005;115(3):572-583. https://doi.org/10.1172/JCI24283.
Abstract
In humans, the biological limitations to cardiac regenerative growth create both a clinical imperative — to offset cell death in acute ischemic injury and chronic heart failure — and a clinical opportunity; that is, for using cells, genes, and proteins to rescue cardiac muscle cell number or in other ways promote more efficacious cardiac repair. Recent experimental studies and early-phase clinical trials lend credence to the visionary goal of enhancing cardiac repair as an achievable therapeutic target.
Authors
Stefanie Dimmeler, Andreas M. Zeiher, Michael D. Schneider
Figure 4
Options:
View larger image
(or click on image)
Download as PowerPoint
Current challenges for cell-based therapy in cardiac repair include identifying the origins of the novel cardiac progenitor and stem cells found within the heart, pinpointing the biologically active cells from bone marrow and other mixed populations, optimizing cell mobilization and homing, augmenting grafted cells’ survival, defining the cues for cardiac differentiation, promoting donor cell proliferation ex vivo (or, if safe, in vivo), and exploiting cell therapy as a platform for secretory signals.
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)